2-amino-5-[[[(1R,4S,5R)-4,5-dihydroxycyclopent-2-en-1-yl]amino]methyl]-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 英文名称: 2-amino-5-[[[(1R,4S,5R)-4,5-dihydroxycyclopent-2-en-1-yl]amino]methyl]-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one
• 化学式: C₁₂H₁₅N₅O₃
• 分子量: 277.28
• InChiKey: WYROLENTHWJFLR-BKPPORCPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.4
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  136
• 氢给体数：
  6
• 氢受体数：
  4

文献信息

• [EN] COMPOUNDS FOR TREATING ALZHEIMER'S DISEASE<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
  申请人：AMABIOTICS

  公开号：WO2019170834A1

  公开（公告）日：2019-09-12

  The present invention relates to a compound of the following formula (I): (I) or a pharmaceutically acceptable salt or hydrate thereof, for use in the prevention or treatment of Alzheimer's disease in an individual.
• [EN] COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES
  申请人：AMABIOTICS

  公开号：WO2021048430A1

  公开（公告）日：2021-03-18

  The present invention relates to a compound of the following formula (I): or a pharmaceutically acceptable salt or hydrate thereof, for use in the prevention or treatment of a neurodegenerative disease selected from the group consisting of a-synucleinopathy, in particular Lewy body disease, Huntington's disease, frontotemporal neurocognitive disorder, and amyotrophic lateral sclerosis in an individual.